Neuromyelitis optica (NMOSD): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

  NCT05909761· Amgen· Source

• Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

  NCT05966467· Alexion Pharmaceuticals, Inc.· Source

• A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

  NCT05199688· Hoffmann-La Roche· Source

• Clinical study testing the efficacy and safety of Ravulizumab in pediatric patients with NMOSD

  2023-508534-33-00· Alexion Pharmaceuticals Inc.· Source

• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

  NCT07557420· Alexion Pharmaceuticals, Inc.· Source

• A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD

  NCT07762872· Junwei Hao, MD· Source

• Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

  NCT05346354· Alexion Pharmaceuticals, Inc.· Source

• lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder

  2024-517176-38-00· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

  NCT05982925· Icahn School of Medicine at Mount Sinai· Source

• The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

  NCT01623076· University of Texas Southwestern Medical Center· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 5
• Gene Expression Profiling 1
• Proteomics 3
• Metabolomics 2
• Flow Cytometry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 79
• Machine Learning 3
• Deep Learning 1
• Cohort Studies 22
• Genome-Wide Association Study 2

See which targets of this disease your abstract mentions, and go to the people working on them.